-
公开(公告)号：EP2902040B1
公开(公告)日：2022-03-23
申请号：EP14187527.8
申请日：2006-10-15
发明人： Cohen, Smadar , Freeman, Inbar
-
公开(公告)号：EP1461014B1
公开(公告)日：2021-07-14
申请号：EP02788510.2
申请日：2002-12-04
IPC分类号： A61K9/127 , C07D303/00 , C07C233/00
-
3.发明授权INHIBITORS OF IgG-A2BG2 FOR USE IN TREATING AND DIAGNOSING AMYOTROPHIC LATERAL SCLEROSIS 有权IgG-A2BG2抑制剂用于治疗和诊断AMYOTROPHIC LATERAL SCLEROSIS
公开(公告)号：EP2788017B1
公开(公告)日：2017-05-31
申请号：EP12813991.2
申请日：2012-12-04
IPC分类号： A61K38/47 , A61K39/395 , A61P25/28
CPC分类号： A61K38/47 , A61K31/428 , C07K16/00 , C07K16/4283 , C07K2317/41 , C07K2317/52 , C07K2317/732 , G01N33/6854 , G01N33/6896 , G01N2800/28
摘要： The present invention provides a method of treating, delaying the onset, delaying progression of, reducing the incidence of or reducing the severity of amyotrophic lateral sclerosis in a subject, the method comprising administering to a subject an agent, which interferes with IgG-A2BG2 expression, IgG-A2BG2 function or IgG-A2BG2 interaction with CD16 in said subject.
摘要翻译： 本发明提供了治疗受试者的肌萎缩性侧索硬化症的发作，延缓其发作，延缓其发展，降低其发生率或降低其严重程度的方法，所述方法包括向受试者施用干扰IgG-A2BG2表达的药剂 ，IgG-A2BG2功能或IgG-A2BG2与所述受试者中的CD16相互作用。
-
公开(公告)号：EP2394323B1
公开(公告)日：2017-05-24
申请号：EP10707973.3
申请日：2010-02-04
发明人： ALFONTA, Lital , FISHILEVICH, Simon , AMIR, Liron
CPC分类号： H01M8/16 , H01M4/86 , H01M4/88 , Y02E60/527 , Y02P70/56
-
公开(公告)号：EP2595991B1
公开(公告)日：2017-04-26
申请号：EP11809371.5
申请日：2011-07-19
申请人： Ben Gurion University of The Negev Research And Development Authority , MOR RESEARCH APPLICATIONS LTD.
发明人： GOLAN, Avi , GOPAS, Jacob , OZER, Janet , EISNER, Nadav , BACHER, Adelbert , EISENREICH, Wolfgang , OSTROZHENKOVA, Elena , WINER, Hila
IPC分类号： A61K36/62 , A61K31/4747 , A61P29/00 , A61P31/12 , A61P35/00
CPC分类号： A61K31/438 , A61K31/4747 , A61K31/7048 , A61K33/24 , A61K36/62 , A61K2300/00
摘要： The current invention provides therapeutic methods which include inhibition of nuclear factor &kgr;b pathway in a cell based on the discovery of an active fraction of a plant extract termed NUP or a composition which includes NUP. NUP is used in treating and managing different diseases such as cancer, inflammation, and virus infections.
摘要翻译： 本发明提供了治疗方法，其包括基于发现称为NUP的植物提取物的活性部分或包含NUP的组合物来抑制细胞中的核因子κB途径。 NUP用于治疗和管理诸如癌症，炎症和病毒感染等不同疾病。
-
6.发明授权SINGLE-STAGE THERMAL PROCESS FOR MANUFACTURING TRANSPARENT SINTERED SPINEL 有权单级的热用于生产透明SINTERSPINELLS
公开(公告)号：EP2280914B1
公开(公告)日：2016-05-04
申请号：EP09754352.4
申请日：2009-07-28
发明人： FRAGE, Nahum , DARIEL, Moshe , MEIR, Shai , KALABUCHOV, Sergei
IPC分类号： C04B35/443 , C04B35/645
CPC分类号： C04B35/443 , C04B35/645 , C04B2235/3203 , C04B2235/3206 , C04B2235/3217 , C04B2235/445 , C04B2235/5409 , C04B2235/5436 , C04B2235/604 , C04B2235/6562 , C04B2235/6567 , C04B2235/666 , C04B2235/72 , C04B2235/721 , C04B2235/77 , C04B2235/96 , C04B2235/9653 , Y10T428/2982
-
公开(公告)号：EP2895202A1
公开(公告)日：2015-07-22
申请号：EP13783679.7
申请日：2013-09-12
发明人： DAVID, Ayelet
IPC分类号： A61K49/00
CPC分类号： A61K49/0054 , A61K49/0032 , A61K49/0034 , C08F122/36
摘要： Highly sensitive imaging of diseased tissues such as cancer is attractive because it potentially allows for early tumor detection. One of the problems associated with conventional, low molecular weight imaging probes is the limited tumor: background ratio. To circumvent this, imaging probes were conjugated to polymeric carriers and were surprisingly found to accumulate specifically at cancer sites. This invention describes an innovative targeting strategy for the selective identification of solid tumors by means of polymer-NIR fluorochrome conjugates which accumulate selectively within cancerous tissue relative to normal tissue.
-
8.发明公开Telomerase activating compounds and their use 审中-公开端粒酶aktivierende Verbindungen und ihre Verwendung
公开(公告)号：EP2826472A3
公开(公告)日：2015-05-20
申请号：EP14183298.0
申请日：2008-06-04
申请人： Ben Gurion University Of The Negev Research And Development Authority , Slavin, Shimon , Gazit, Aviv
发明人： Priel,Esther , Yitzchak, Sara , Gazit, Aviv , Slavin, Shimon
IPC分类号： A61K31/03 , A61K31/05 , A61K31/055 , A61K31/136 , A61K31/66 , A61K31/695 , C07C215/50 , C07D295/096 , C07D213/16 , C07D213/30
CPC分类号： C07C215/80 , A61K31/03 , A61K31/05 , A61K31/055 , A61K31/136 , A61K31/66 , A61K31/695 , C07C39/367 , C07C43/225 , C07C43/23 , C07C215/50 , C07D213/16 , C07D213/30 , C07D295/096 , C07D295/135 , C07F9/5022
摘要： The present invention is directed to use of a series of compounds represented by the structure of formula I and compositions comprising the same for activating telomerase and treating diseases, disorders and/or conditions related thereto:
摘要翻译： 本发明涉及使用由式I结构表示的一系列化合物及其组合物，用于活化端粒酶和治疗与之相关的疾病，病症和/或病症：
-
9.发明公开COMBINED THERAPY OF ALPHA-1-ANTITRYPSIN AND TEMPORAL T-CELL DEPLETION FOR PREVENTING GRAFT REJECTION 审中-公开ALPHA-1抗胰蛋白酶联合治疗，和时间T细胞消耗用于抑制移植
公开(公告)号：EP2819698A1
公开(公告)日：2015-01-07
申请号：EP13755285.7
申请日：2013-02-27
发明人： LEWIS, Eli
IPC分类号： A61K39/395 , A61K38/55 , A61P37/06
CPC分类号： A61K39/395 , A61K35/39 , A61K38/14 , A61K38/191 , A61K38/217 , A61K38/57 , A61K39/39541 , A61K39/3955 , A61K2039/505 , C07K16/40 , A61K2300/00
摘要： The present invention provides compositions and methods for the prevention and treatment of aggressive immune processes to life-saving grafts, such as xenograft rejection, and for attenuating host responses in transplantation of tissues, cells and organs. More specifically, the compositions and methods of the present invention relate to combined therapies comprising treatment of alpha-1-antitrypsin (AAT) and temporary T-cell depletion including but not limited to anti-CD4 and anti-CD8 antibodies.
-
公开(公告)号：EP2754187A1
公开(公告)日：2014-07-16
申请号：EP12790685.7
申请日：2012-09-09
申请人： Yeda Research and Development Co. Ltd , Ben Gurion University of The Negev Research and Development Authority
发明人： IMRY, Yoseph , ENTIN-WOHLMAN, Ora , JIANG, JianHua
IPC分类号： H01L35/32
摘要： An efficiency-enhanced, three-terminal, bi-junction thermoelectric device driven by independently-adjustable parameters of temperature and voltage.
-
-
-
-
-
-
-
-
-
搜索结果
256 条记录 (耗时 0.048 秒)
